Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.

Journal of experimental & clinical cancer research : CR - 17 Mar 2011

Sun Leina, Zhang Qiang, Luan Huanling, Zhan Zhongli, Wang Changli, Sun Baocun

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have been widely used for the treatment of non-small cell lung cancer (NSCLC). KRAS and EGFR somatic mutations in NSCLC may predict resistance and responsiveness to TKI, respectively. Nevertheless, most research to date has been conducted on samples from primary tumors. For many patients with advanced disease, their samples can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lymph Nodes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21414214
DOI: 10.1186/1756-9966-30-30
PMCID: PMC3069944

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.PMID 21414214Read ↗

[KRAS and epidermal growth factor receptor gene mutation in non-small cell lung cancer].Semantic proximity Read ↗

[Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].Semantic proximity Read ↗

Comparison of epidermal growth factor receptor mutations between primary tumors and lymph nodes in non-small cell lung cancer: a review and meta-analysis of published data.Semantic proximity Read ↗

Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.Semantic proximity Read ↗

Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer.Semantic proximity Read ↗

EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis.Semantic proximity Read ↗

Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers.Semantic proximity Read ↗

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.Semantic proximity Read ↗

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.Semantic proximity Read ↗

EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis.Semantic proximity Read ↗

KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.Semantic proximity Read ↗

EGFR and KRAS mutations in metastatic lung adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.